Search research articles
Contact Us
Filters
Showing results (891-900 of 934) with videos related to
Page
of 94
Sort By:
Thrombosis Research
|
July 21, 2020
Safety and efficacy of drug eluting stents vs bare metal stents in patients with atrial fibrillation: A systematic review and meta-analysis
Antonia Sambola, Pau Rello, Toni Soriano, et al.
Diabetes, Obesity & Metabolism
|
March 26, 2021
The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial
Clare Arnott, Jing-Wei Li, Christopher P Cannon, et al.
Journal of the American Heart Association
|
June 23, 2016
Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease
Lars Wallentin, Claes Held, Paul W Armstrong, et al.
European Heart Journal
|
November 28, 2025
A polygenic risk score for peripheral artery disease and major adverse limb events
Samer Al Said, Siddharth M Patel, Giorgio E M Melloni, et al.
BMJ Open Diabetes Research & Care
|
June 13, 2023
Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering
David M Charytan, Kenneth W Mahaffey, Meg J Jardine, et al.
Critical Pathways in Cardiology
|
March 15, 2008
Implications of the mechanical (PCI) vs thrombolytic controversy for ST segment elevation myocardial infarction on the organization of emergency medical services: the Boston EMS experience
Peter Moyer, James Feldman, Jon Levine, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
November 20, 2020
Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m<sup>2</sup>: Subgroup Analysis of the Randomized CREDENCE Trial
George Bakris, Megumi Oshima, Kenneth W Mahaffey, et al.
The New England Journal of Medicine
|
November 17, 2020
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
Deepak L Bhatt, Michael Szarek, P Gabriel Steg, et al.
JAMA Cardiology
|
November 9, 2022
Results of a Remotely Delivered Hypertension and Lipid Program in More Than 10 000 Patients Across a Diverse Health Care Network
Alexander J Blood, Christopher P Cannon, William J Gordon, et al.
Journal of the American Heart Association
|
August 5, 2022
Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial
Jing-Wei Li, Clare Arnott, Hiddo J L Heerspink, et al.
Page
of 94
Search research articles
Search
Showing results (891-900 of 934) with videos related to
Sort By:
Page
of 94
Thrombosis Research
|
July 21, 2020
Safety and efficacy of drug eluting stents vs bare metal stents in patients with atrial fibrillation: A systematic review and meta-analysis
Antonia Sambola, Pau Rello, Toni Soriano, et al.
Diabetes, Obesity & Metabolism
|
March 26, 2021
The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial
Clare Arnott, Jing-Wei Li, Christopher P Cannon, et al.
Journal of the American Heart Association
|
June 23, 2016
Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease
Lars Wallentin, Claes Held, Paul W Armstrong, et al.
European Heart Journal
|
November 28, 2025
A polygenic risk score for peripheral artery disease and major adverse limb events
Samer Al Said, Siddharth M Patel, Giorgio E M Melloni, et al.
BMJ Open Diabetes Research & Care
|
June 13, 2023
Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering
David M Charytan, Kenneth W Mahaffey, Meg J Jardine, et al.
Critical Pathways in Cardiology
|
March 15, 2008
Implications of the mechanical (PCI) vs thrombolytic controversy for ST segment elevation myocardial infarction on the organization of emergency medical services: the Boston EMS experience
Peter Moyer, James Feldman, Jon Levine, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
November 20, 2020
Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m<sup>2</sup>: Subgroup Analysis of the Randomized CREDENCE Trial
George Bakris, Megumi Oshima, Kenneth W Mahaffey, et al.
The New England Journal of Medicine
|
November 17, 2020
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
Deepak L Bhatt, Michael Szarek, P Gabriel Steg, et al.
JAMA Cardiology
|
November 9, 2022
Results of a Remotely Delivered Hypertension and Lipid Program in More Than 10 000 Patients Across a Diverse Health Care Network
Alexander J Blood, Christopher P Cannon, William J Gordon, et al.
Journal of the American Heart Association
|
August 5, 2022
Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial
Jing-Wei Li, Clare Arnott, Hiddo J L Heerspink, et al.
Page
of 94